advances-in-protein-chemistry

91. Han YP, Tuan TL, Wu H, Hughes M, Garner WL (2001) TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated
induction of MT1-MMP. J Cell Sci 114: 131-139.
92. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor
agents. Cancer Res 59: 2615-2622.
93. Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, et al. (2001) A synthetic triterpenoid selectively inhibits the induction of matrix
metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum 44: 1096-1104.
94. Pan MR, Chuang LY, Hung WC (2001) Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of
transcription in lung cancer cells. FEBS Lett 508: 365-368.
95. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, et al. (1999) p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene
expression. J Biol Chem 274: 11535-11540.
96. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, et al. (2000) Wild type and mutant p53 differentially regulate the gene expression of
human collagenase-3 (hMMP-13). J Biol Chem 275: 11327-11332.
97. Ala-aho R, Grénman R, Seth P, Kähäri VM (2002) Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous
carcinoma cells. Oncogene 21: 1187-1195.
98. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, et al. (1999) Functional overlap between two classes of matrix-degrading proteases in wound
healing. EMBO J 18: 4645-4656.
99. Van Lent PL, Holthuysen AE, Sloetjes A, Lubberts E, Van den Berg WB (2002) Local overexpression of adeno-viral IL-4 protects cartilage from metallo
proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthritis Cartilage 10: 234-243.
100. Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, et al. (2002) Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2
secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta 1542: 209-220.
101. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, et al. (2001) Furin inhibition results in absent or decreased invasiveness and
tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 98: 10326-10331.
102. Khatib AM, Siegfried G, Chrétien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in
cancer therapy. Am J Pathol 160: 1921-1935.
103. Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G, et al. (1998) Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by
a synthetic furin inhibitor. FEBS Lett 424: 262-266.
104. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, et al. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.
Nature 348: 699-704.
105. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, et al. (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and
catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413.
106. Nakada M, Yamada A, Takino T, Miyamori H, Takahashi T, et al. (2001) Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated
MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res 61: 8896-8902.
107. Overall CM, Tam E, McQuibban GA, Morrison C, Wallon UM, et al. (2000) Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation
complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem
275: 39497-39506.
108. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, et al. (2001) Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-
2-independent pathway. J Biol Chem 276: 47402-47410.
109. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
110. Huang X, Chen S, Xu L, Liu Y, Deb DK, et al. (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion
in human prostate epithelial cells. Cancer Res 65: 3470-3478.
111. Lambert E, Dassé E, Haye B, Petitfrère E (2004) TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49: 187-198.
112. Wang S, Cheng Y, Wang F, Sun L, Liu C, et al. (2008) Inhibition activity of sulfated polysaccharide of Sepiella maindroni ink on matrix metalloproteinase
(MMP)-2. Biomed Pharmacother 62: 297-302.
113. Berton A, Rigot V, Huet E, Decarme M, Eeckhout Y, et al. (2001) Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A
and B by long-chain unsaturated fatty acids. J Biol Chem 276: 20458-20465.
114. Dai JR, Hallock YF, Cardellina JH II, Gray GN, Boyd MR (1996) Triangulynes A-H and trangulynic acid, new cytotxic polyacetylenes from the marine
sponge Pellina triangulata. J Nat Prod 59: 860-865.
115. Li HY, Matsunaga S, Fusetani N (1994) Corticatic acids A-C, antifungal acetylenic acids from the marine sponge, Petrosia corticata. J Nat Prod 57:
1464-1467.
116. Tsukamoto S, Kato H, Hirota H, Fusetani N (1997) Mauritiamine, a new antifouling oroidin dimer from the marine sponge Agelas mauritiana. J Nat
Prod 60: 126–130.
117. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, et al. (2001) Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic
compound. Anticancer Res 21: 145-155.
118. Lødemel JB, Egge-Jacobsen W, Olsen RL (2004) Detection of TIMP-2-like protein in Atlantic cod (Gadus morhua) muscle using two-dimensional realtime
reverse zymography. Comp Biochem Physiol B Biochem Mol Biol 139: 253-259.
119. Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL, et al. (2007) The evolution of the vertebrate metzincins; insights from Ciona intestinalis
and Danio rerio. BMC Evol Biol 7: 63.
120. Suomalainen K, Sorsa T, Golub LM, Ramamurthy N, Lee HM, et al. (1992) Specificity of the anticollagenase action of tetracyclines: relevance to their
anti-inflammatory potential. Antimicrob Agents Chemother 36: 227-229.
121. Lelièvre Y, Bouboutou R, Boiziau J, Cartwright T (1989) [Inhibition of synovial collagenase by actinonin. Study of structure/activity relationship]. Pathol
Biol (Paris) 37: 43-46.
122. Fujita M, Nakao Y, Matsunaga S, Seiki M, Itoh Y, et al. (2003) Ageladine A: an antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge
Agelas nakamurai. J Am Chem Soc 125: 15700-15701.
123. Wang J, Willumsen N, Zheng Q, Xue Y, Karsdal MA, et al. (2013) Bringing cancer serological diagnosis to a new level: focusing on HER2, protein
ectodomain shedding and neoepitope technology. Future Oncol 9: 35-44.
124. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:
617-629.
125. Johnson PR (2001) Role of human airway smooth muscle in altered extracellular matrix production in asthma. Clin Exp Pharmacol Physiol 28: 233-236.
OMICS Group eBooks
018